Skip to main content
CURLF
OTC Life Sciences

Curaleaf Sets December 1 Tender Deadline and Hosts Q&A in Push for Aurora Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$10.06
Mkt Cap
$2.664B
52W Low
$5.4
52W High
$15.15
52W Position info
86% above low
Off High info
34% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CURLF sits 86% above its 52-week low of $5.4.

Summary

Curaleaf sent a letter to Aurora shareholders urging them to tender shares by December 1, 2026, and announced a live Q&A with CEO Boris Jordan on September 17. The letter adds new comparative performance data attacking Aurora's standalone plan.


Key Events · M&A and Partnerships · CURLF

  • Shareholder Letter Urges Tender

    A letter to Aurora shareholders urges them to accept the US$4.00 per share offer, a 45% premium to the August 10 VWAP, and tender their shares.

  • Tender Deadline Set for December 1

    The letter specifies that Aurora shareholders must tender their shares before December 1, 2026.

  • Live Q&A Announced

    Chairman and CEO Boris Jordan will host a live shareholder Q&A on Thursday, September 17, 2026 at 10:30 a.m. ET, with registration at grow.curaleaf.com.

  • Comparative Performance Data

    In the first six months of 2026, Curaleaf shares rose approximately 50% while Aurora shares declined approximately 34%; over the four quarters ended June 30, 2026, Aurora's net revenue and adjusted EBITDA declined 14% and 78% respectively.


Analysis · CURLF · Life Sciences

The hostile takeover campaign for Aurora Cannabis is entering a more urgent phase, with Curaleaf adding a December 1, 2026 tender deadline and a live Q&A with CEO Boris Jordan on September 17. The shareholder letter also sharpens the attack with fresh comparative data: Aurora's revenue fell 14% and adjusted EBITDA dropped 78% over the trailing four quarters, while Curaleaf shares rose 50% in the first half of 2026 versus Aurora's 34% decline. This is the latest in a series of 425 filings aimed at pressuring Aurora shareholders to accept the US$4.00 per share offer, a 45% premium to the August 10 VWAP. The new deadline and Q&A event give the campaign concrete next steps, though the core offer terms remain unchanged from the August 18 launch.

How filings like this one have moved

In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CURLF was trading at $10.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CURLF - Latest Insights

CURLF
Sep 15, 2026, 3:56 PM EDT
Filing Type: 8-K
Importance Score:
7
CURLF
Sep 14, 2026, 3:30 PM EDT
Filing Type: 425
Importance Score:
8
CURLF
Sep 14, 2026, 3:30 PM EDT
Filing Type: 8-K
Importance Score:
8
CURLF
Sep 08, 2026, 5:08 PM EDT
Filing Type: 425
Importance Score:
8
CURLF
Sep 02, 2026, 1:15 PM EDT
Filing Type: 425
Importance Score:
8